Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223

BACKGROUND: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. PATIENTS AND METHODS: Patients with histologically confirmed progressive CRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Gallicchio, Rosj, Bozza, Giovanni, Rodriquenz, Maria Grazia, Aieta, Michele, Storto, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301292/
https://www.ncbi.nlm.nih.gov/pubmed/30588025
http://dx.doi.org/10.2147/OTT.S174206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301292/
https://www.ncbi.nlm.nih.gov/pubmed/30588025
http://dx.doi.org/10.2147/OTT.S174206

Ejemplares similares